We are live on ! Find out more
KITE

Kite Pharma
KITE

Delisted

KITE was delisted on the 2nd of October, 2017.

62 hedge funds and large institutions have $273M invested in Kite Pharma in 2014 Q3 according to their latest regulatory filings, with 60 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

6,315% more capital inflows, than outflows

Capital inflows: $236M | Capital outflows: $3.68M

1,900% more first-time investments, than exits

New positions opened: 60 | Existing positions closed: 3

1,140% more funds holding

Funds holding: 5 → 62 (+57)

24.57% more ownership

Funds ownership: 0.63% → 25.2% (+25%)

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

Holders
62
Holders Change
+57
Holders Change %
+1,140%
% of All Funds
1.79%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.03%
New
60
Increased
1
Reduced
1
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

KITE Hedge Fund Activity: Q3 2014 in Review

62 of the 3,455 institutional investors tracked by Wall St. Rank reported a position in Kite Pharma (KITE) for Q3 2014, worth a combined $273M — up 3,812% from $6.98M a quarter earlier.

Buyers outnumbered sellers: 60 funds opened new KITE positions and 3 closed out — a net gain of 57 holders — while 1 added to existing stakes and 1 trimmed.

The largest buyer was Capital Research Global Investors, opening a new position worth an estimated $59.1M. The largest seller was Alyeska Investment Group, exiting entirely with an estimated $1.82M sold.

  • 62 institutional investors held Kite Pharma (KITE) as of Q3 2014, up from 5 in Q2 2014.
  • Funds reported $273M of Kite Pharma stock for Q3 2014, up 3,812% quarter-over-quarter.
  • 60 funds opened new Kite Pharma positions in Q3 2014 and 3 closed out, a net change of +57 holders.
  • The largest Kite Pharma buyer in Q3 2014 was Capital Research Global Investors, an estimated $59.1M added.
  • The largest Kite Pharma seller in Q3 2014 was Alyeska Investment Group, an estimated $1.82M sold.

Based on aggregated 13F filings for Q3 2014.